ACE Inhibitor

ACE inhibitors are a foundational class of cardiovascular medicines that block angiotensin-converting enzyme (ACE), an enzyme responsible for converting angiotensin I into angiotensin II - a potent vasoconstrictor. By blocking this conversion, ACE inhibitors lower blood pressure, reduce strain on the heart, and protect kidney function in many disease states. The class includes lisinopril, enalapril, ramipril, captopril, benazepril, and several others, all sharing the suffix '-pril'.

Mechanistically, ACE inhibitors interrupt the renin-angiotensin-aldosterone system (RAAS), a hormonal pathway that regulates blood pressure and fluid balance. With less angiotensin II, blood vessels relax (vasodilation), aldosterone secretion drops (reducing sodium and water retention), and pressure inside the glomeruli of the kidneys decreases. A useful side effect of this mechanism is the accumulation of bradykinin, which contributes to vasodilation but is also responsible for the characteristic dry cough that affects up to 20% of patients.

Clinically, ACE inhibitors are first-line therapy for hypertension, heart failure with reduced ejection fraction, post-myocardial infarction, and diabetic kidney disease. Landmark trials such as SOLVD, HOPE, and CONSENSUS established their ability to reduce mortality, slow progression of kidney disease, and prevent cardiovascular events. They are particularly valuable in patients with diabetes because they protect against diabetic nephropathy independent of their blood pressure-lowering effect.

A common misconception is that all blood pressure medications are interchangeable. ACE inhibitors differ from ARBs (angiotensin II receptor blockers) - both block the RAAS, but at different points. ACE inhibitors cause cough and a slightly higher risk of angioedema; ARBs generally do not. Another misconception is that a mild rise in serum creatinine after starting an ACE inhibitor indicates kidney damage. In fact, a modest increase (up to 30%) often reflects intended hemodynamic effects within the glomerulus and is associated with long-term kidney protection.

Key safety considerations include hyperkalemia (especially with kidney disease or potassium-sparing diuretics), angioedema (a rare but life-threatening swelling of the face and airway), and absolute contraindication in pregnancy due to fetal kidney malformations. Patients should be educated about the cough, monitored for potassium and creatinine after initiation, and warned to seek emergency care for any facial or throat swelling.

For patients with diabetic kidney disease, ACE inhibitors remain a class I recommendation across major guidelines because of their ability to slow proteinuria and preserve glomerular filtration rate. They are also commonly combined with diuretics (for blood pressure) or beta blockers (for heart failure), although combining ACE inhibitors with ARBs or direct renin inhibitors is generally avoided due to higher rates of hyperkalemia, hypotension, and acute kidney injury without proven mortality benefit. In African American populations, ACE inhibitors are slightly less effective as monotherapy for blood pressure compared with calcium channel blockers or thiazides, though they retain their organ-protective benefits and are still recommended when proteinuria or heart failure is present.